Get the Stockscreener App
1.173
2.89%
0.033
Neurosense Therapeutics Ltd stock is traded at $1.173, with a volume of 88,340.
It is up +2.89% in the last 24 hours and down -39.16% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$1.14
Open:
$1.14
24h Volume:
88,340
Relative Volume:
0.24
Market Cap:
$30.75M
Revenue:
-
Net Income/Loss:
$-13.76M
P/E Ratio:
-1.2613
EPS:
-0.93
Net Cash Flow:
-
1W Performance:
-1.43%
1M Performance:
-39.16%
6M Performance:
+7.61%
1Y Performance:
+41.84%
1-Day Range:
$1.14
$1.19
1-Week Range:
$1.07
$1.3296
52-Week Range:
$0.6729
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.173 | 30.75M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
Watch for Trend Continuation in NeuroSense Therapeutics Ltd. Next WeekJuly 2025 Big Picture & Weekly Stock Breakout Alerts - newsyoung.net
Published on: 2025-08-21 02:05:04 - thegnnews.com
NeuroSense Reports Long-Term Safety of PrimeC in ALS Study - TipRanks
Using Python tools to backtest NeuroSense Therapeutics Ltd. strategiesJuly 2025 Summary & Daily Stock Trend Reports - Newser
How to recover losses in NeuroSense Therapeutics Ltd. stockPortfolio Performance Report & Daily Volume Surge Trade Alerts - Newser
What the charts say about NeuroSense Therapeutics Ltd. todayJuly 2025 Summary & Precise Swing Trade Entry Alerts - Newser
Published on: 2025-08-20 21:29:02 - thegnnews.com
NeuroSense Therapeutics Ltd. Equity Warrant Uptrend in Early Stages Indicators Say YesMarket Growth Report & Free Fast Gain Swing Trade Alerts - beatles.ru
Published on: 2025-08-20 21:57:00 - mustnews.co.kr
Will breakout in NeuroSense Therapeutics Ltd. lead to full recoveryJuly 2025 Setups & Entry and Exit Point Strategies - Newser
Historical volatility pattern of NeuroSense Therapeutics Ltd. visualized2025 Growth vs Value & Daily Stock Trend Reports - Newser
Building trade automation scripts for NeuroSense Therapeutics Ltd. Equity Warrant2025 Support & Resistance & Daily Risk Controlled Trade Plans - Newser
Long term hold vs stop loss in NeuroSense Therapeutics Ltd.Earnings Growth Summary & Free Community Supported Trade Ideas - Newser
Real time social sentiment graph for NeuroSense Therapeutics Ltd.2025 Market Outlook & Daily Stock Momentum Reports - Newser
Does NeuroSense Therapeutics Ltd. Equity Warrant qualify in momentum factor screeningJuly 2025 Trends & Community Verified Trade Signals - Newser
Can NeuroSense Therapeutics Ltd. Equity Warrant hit a new high this monthPortfolio Risk Summary & Weekly Breakout Watchlists - Newser
Is it time to cut losses on NeuroSense Therapeutics Ltd. Equity WarrantIPO Watch & High Return Stock Watch Alerts - Newser
Reversal indicators forming on NeuroSense Therapeutics Ltd. stockJuly 2025 Institutional & Free Weekly Chart Analysis and Trade Guides - Newser
Measuring NeuroSense Therapeutics Ltd. Equity Warrant’s beta against major indicesQuarterly Profit Report & Accurate Technical Buy Alerts - Newser
Full technical analysis of NeuroSense Therapeutics Ltd. Equity Warrant stockJuly 2025 Rallies & Long Hold Capital Preservation Plans - Newser
How sentiment analysis helps forecast NeuroSense Therapeutics Ltd.Market Growth Summary & Weekly Setup with High ROI Potential - Newser
Is NeuroSense Therapeutics Ltd. forming a bottoming baseTrade Entry Report & Consistent Profit Alerts - Newser
Risk vs reward if holding onto NeuroSense Therapeutics Ltd. Equity WarrantJuly 2025 Market Mood & Advanced Technical Analysis Signals - Newser
NeuroSense Therapeutics Ltd. stock trendline breakdownJuly 2025 Macro Moves & Accurate Intraday Trade Tips - Newser
Published on: 2025-08-19 08:13:41 - newsimpact.co.kr
NeuroSense Therapeutics Ltd.’s volatility index tracking explainedJuly 2025 Highlights & Free Real-Time Market Sentiment Alerts - Newser
NEUROSENSE THERAPEUTICS LTD. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023 - The Globe and Mail
What indicators show strength in NeuroSense Therapeutics Ltd.Quarterly Trade Review & Risk Adjusted Buy/Sell Alerts - Newser
Should you hold or exit NeuroSense Therapeutics Ltd. nowBreakout Watch & Free Risk Controlled Daily Trade Plans - Newser
NeuroSense Therapeutics Ltd. Pullback Analyzed — Is It Time to ExitJuly 2025 Macro Moves & Technical Confirmation Trade Alerts - sundaytimes.kr
What to expect from NeuroSense Therapeutics Ltd. Equity Warrant in the next 30 daysJuly 2025 Selloffs & Free Community Consensus Stock Picks - Newser
Pattern recognition hints at NeuroSense Therapeutics Ltd. upsideTrade Risk Summary & Safe Entry Zone Identification - Newser
What institutional flow reveals about NeuroSense Therapeutics Ltd. Equity WarrantMarket Weekly Review & Momentum Based Trading Ideas - Newser
Can NeuroSense Therapeutics Ltd. weather a recessionProfit Target & Consistent Growth Stock Picks - sundaytimes.kr
NeuroSense Therapeutics Ltd. Equity Warrant stock retracement – recovery analysisWatch List & Weekly Breakout Stock Alerts - Newser
Applying chart zones and confluence areas to NeuroSense Therapeutics Ltd. Equity Warrant2025 Market Trends & Low Risk High Win Rate Stock Picks - Newser
Is NeuroSense Therapeutics Ltd.’s ROIC above industry averageMarket Sentiment Summary & Community Consensus Trade Alerts - 선데이타임즈
Traders Consider Averaging Down in NeuroSense Therapeutics Ltd. Equity WarrantJuly 2025 Pullbacks & Capital Protection Trade Alerts - 선데이타임즈
Market reaction to NeuroSense Therapeutics Ltd.’s recent newsEarnings Growth Report & Verified Technical Signals - Newser
Published on: 2025-08-11 02:20:37 - Newser
Why NeuroSense Therapeutics Ltd. stock attracts strong analyst attentionFree Day Trading Signals With High Precision - Newser
Why NeuroSense Therapeutics Ltd. is moving todayFree Stock Screener With Smart Filters - Newser
Chart based exit strategy for NeuroSense Therapeutics Ltd.Weekly Outlook for Short Term Investors - Newser
Detecting price anomalies in NeuroSense Therapeutics Ltd. Equity Warrant with AIAlgorithmic Prediction of Market Breakouts - Newser
How hedge fund analytics apply to NeuroSense Therapeutics Ltd. stockSmart Money Strategy for Growth Stocks - Newser
NeuroSense Therapeutics Ltd. Equity Warrant Company Revenue and Profit Trends: A Deep DiveSecure Entry Point Finder with Analysis - Newser
Maxim Group Analyst Maintains Hold Rating on Neurosense Therapeutics Ltd. - AInvest
What Fibonacci levels say about NeuroSense Therapeutics Ltd. reboundReal-Time AI Generated Market Forecast - Newser
Should you wait for a breakout in NeuroSense Therapeutics Ltd.Early Buy Opportunity with Chart Triggers - Newser
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):